Symbiotec Pharmalab Receives US FDA Inspection Report for Pithampur Facility
Symbiotec Pharmalab received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (US FDA) for its Pithampur manufacturing facility in Madhya Pradesh. The inspection took place from August 10 to 14, 2026. Despite a 7% revenue increase to Rs 218.2 crore in Q1 FY27, the company reported a 52.8% decline in consolidated net profit to Rs 14.1 crore during the same period.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 38/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 29 Sept, 05:53 am. Other outlets followed.
- 1businessstandard29 Sept, 05:53 amSymbiotec Pharmalab surges after Pithampur facility gets EIR from US FDA
- 2businessstandard29 Sept, 07:11 amSymbiotec Pharmalab receives EIR report for Pithampur SEZ unit
Who's involved
Institutions and figures named across source coverage.
Story context
- Category
- Business
- Location
- Pithampur, India
- Sources analysed
- 2
- Last analysed
- 29 Sept 2026
- Key entities
- Food and Drug AdministrationPithampurSpecial economic zoneIndian rupeeMadhya PradeshCroreIndiaPharmaceutical industryBiotechnologyUnited StatesSmall and medium-sized enterprisesHimalayas